CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness.

Area of Science:

• Hematology
• Oncology
• Immunophenotyping

Background:

• BCR-ABL1 gene rearrangements are critical for prognostic stratification and treatment in B-cell acute lymphoblastic leukemia (B-ALL).
• Accurate identification of BCR-ABL1 positive B-ALL is essential for patient management.
• Flow cytometry is a key diagnostic tool in B-ALL, with ongoing research into novel markers.

Purpose of the Study:

• To evaluate the expression of the myeloid antigen CD66c in B-ALL patients.
• To determine the correlation between CD66c expression and BCR-ABL1 gene rearrangements.
• To assess the utility of CD66c as a diagnostic marker in B-ALL.

Main Methods:

• Flow cytometry was used to analyze CD66c expression in 94 B-ALL patients.
• BCR-ABL1 rearrangement was confirmed by cytogenetic analysis or RT/PCR.
• Expression of other myeloid antigens (CD13, CD33, CD117, MPO, CD15, CD65) was also assessed.

Main Results:

• CD66c was expressed in 40% of B-ALL cases and was the most frequent myeloid antigen on lymphoblasts.
• CD66c expression showed a significant correlation with BCR-ABL1 rearrangements (sensitivity 82%, specificity 69%).
• Co-expression of CD66c and CD13 was more common in BCR-ABL1 positive cases, though some BCR-ABL1 negative cases also expressed CD66c.

Conclusions:

• CD66c expression is a valuable indicator correlated with BCR-ABL1 rearrangement in B-ALL, but not entirely specific.
• The absence of CD66c expression strongly suggests the absence of BCR-ABL1 rearrangement.
• CD66c may hold potential for detecting minimal residual disease in B-ALL.